Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

por Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K
Publicado 2011